Approximately 9,000 individuals are diagnosed with Hodgkin lymphoma each year in the United States. Most patients are diagnosed between the ages of 15 and 30 years, followed by another peak at age 55 and older. 
Significant progress has been made in the treatment of patients with Hodgkin lymphoma, with cure rates of 80% or higher using chemotherapeutic approaches.  New active agents (e.g., bendamustine and brentuximab) have been introduced that can help control relapsed or refractory Hodgkin lymphoma in order to allow procession to transplant [3,4]
An accurate assessment of the stage of disease in patients with Hodgkin lymphoma is critical for the selection of the appropriate therapy.  Prognostic models that identify patients at low or high risk for recurrence are used to optimize therapy for patients with limited or advanced stage disease.  Hematopoietic cell transplantation (HCT), often autologous but occasionally allogeneic, can be used for recurrent disease.
Review outcomes for allogeneic and autologous HCT in patients with Hodgkin lymphoma below. View additional Hodgkin Lymphoma slides showing demographic data and transplant trends.
Data in this section have been prepared by CIBMTR® (Center for International Blood and Marrow Transplant Research), our research program.
Figure 1: Hodgkin Lymphoma Survival, Unrelated HCT
Figure 2. Hodgkin Lymphoma Survival, Autologous HCT, by Disease Status
Figure 3. Hodgkin Lymphoma Survival, Allogeneic HCT, by Donor Type
Referral Timing Guidelines
These guidelines highlight disease categories that include patients at risk for disease progression and who should be referred for a consultation for autologous or allogeneic transplantation. 
Transplant Consultation Guidelines: Hodgkin Lymphoma
- Primary induction failure
- At first or subsequent relapse
- CR2 or subsequent remission
- SEER Stat Fact Sheets: Hodgkin Lymphoma. Website accessed May 1, 2015. Access
- National Comprehensive Cancer Network (NCCN) Guidelines: Hodgkin Lymphoma, version 2.2013; page MS-2. Access
- Moscowitz AJ. Novel agents in Hodgkin lymphoma. Curr Oncol Rep. 2012; 14(5): 419-423. Access
- Zinzani PL, Derenzini E, Pellegrini C, et al. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. Br J Haematol. 2013; 163(5): 681-683. Access
- Perales M-A, Ceberio I, Armand P, et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015; 21(6): 971-983. Access
- Ansell, SM. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012; 87(12): 1096-1103. Access
- NMDP/Be The Match & ASBMT Recommended Timing for Transplant Consultation, 2016. Download (PDF)